Peter Staley — the trader who took down AZT's price.

Start here

The short version: Peter Staley (born January 9, 1961) was a Wall Street bond trader diagnosed with AIDS-related complex in 1985 at age 24. He joined ACT UP New York in early 1987, chaired its fundraising committee, and in 1988 quit Wall Street to become a full-time HIV activist.1 On September 14, 1989, he led five ACT UP members onto the floor of the New York Stock Exchange, chained themselves to the VIP balcony, and unfurled a banner reading "SELL WELLCOME." Three days later, Burroughs Wellcome cut the price of AZT by 20% — the first documented drug-price rollback in U.S. history caused by a direct-action protest.2 In 1992 he founded the Treatment Action Group (TAG), which continues to be one of the most influential HIV treatment-research advocacy organizations in the world.3 He is featured in David France's Oscar-nominated 2012 documentary How to Survive a Plague and published his memoir Never Silent: ACT UP and My Life in Activism in October 2021.4

He is 65 years old. He is undetectable. He is still working.

Who is Peter Staley

Peter Staley grew up in a Republican family in Sacramento; his father was a General Electric executive who became a labor negotiator. Staley studied piano seriously through his teens, considered a career as a concert pianist, and pivoted at Oberlin toward finance. By 1984 he was on a JP Morgan trading floor in New York, closeted, and doing well. And then, in the middle of watching the made-for-TV movie An Early Frost in November 1985, he recognized his own night sweats in the actor Aidan Quinn's character.5

The 1985 diagnosis and the Wall Street double life

Staley called his physician the morning after An Early Frost aired. Dr. Dan William confirmed HIV infection and AIDS-related complex — the pre-AIDS classification used at the time. Staley kept his diagnosis secret from JP Morgan. He continued working the bond desk by day and started attending ACT UP meetings at the New York Gay and Lesbian Community Services Center at 208 West 13th Street by night. Larry Kramer had founded ACT UP on March 12, 1987, weeks before Staley walked in for the first time.6

What Staley brought to ACT UP that most members did not: capital-markets fluency. He understood equity valuation, options pricing, corporate governance, and how pharmaceutical companies actually made decisions. That knowledge would produce the single most consequential action in the history of AIDS activism.

September 14, 1989 — the NYSE floor protest

By 1989, AZT (zidovudine, brand name Retrovir) was still the only FDA-approved HIV antiretroviral. Its manufacturer, Burroughs Wellcome (later part of GlaxoSmithKline), was charging approximately $8,000 per patient per year in 1989 dollars — more than $20,000 in 2026 dollars. It was, at the time, the most expensive prescription drug ever brought to market. Federal support for AZT's development, through the NIH, had been substantial. ACT UP's Treatment & Data Committee, which Staley co-led, saw an obvious argument: taxpayers paid to develop the drug, and Wellcome was gouging the sick people they helped create.7

The plan, developed by Staley and ACT UP's James McGrath, was audacious and specific. On the morning of September 14, 1989, five ACT UP members — Staley, McGrath, Robert Hilferty, Scott Robbe, and Richard Elovich — entered the New York Stock Exchange building at 11 Wall Street, using forged VIP passes Staley had obtained through his still-active Wall Street contacts. They chained themselves to the VIP balcony overlooking the trading floor. They unfurled a banner reading "SELL WELLCOME." They blew marine air horns to drown out the opening bell.2

All five protesters were arrested on charges of criminal trespass and disorderly conduct. All charges were later dropped or dismissed. The template Staley created that morning — using capital-markets pressure and shareholder mechanisms to force pharmaceutical price reductions — has been used by AIDS activists, mental-health advocates, insulin-price activists, and cancer patients ever since.8

Founding the Treatment Action Group — 1992

By 1991, ACT UP was fracturing. Some members wanted to maintain a broad social-justice agenda; others believed treatment science needed a specialized, scientifically literate, professionalized organization to sit at NIH, FDA, and pharma tables. In January 1992, Staley and a group of ACT UP Treatment & Data Committee members — including Mark Harrington, Gregg Gonsalves, David Barr, and Spencer Cox — formally split from ACT UP to form the Treatment Action Group (TAG). Staley was TAG's founding director.9

TAG went on to help drive the FDA parallel-track program, the design of protease-inhibitor clinical trials that would produce the 1996 combination-therapy breakthrough, and NIH tuberculosis and hepatitis C research reforms. It is still funded, still working, and still centered on the same original insight: activists with scientific literacy sitting inside drug-development processes save lives.3

The Jesse Helms condom — September 5, 1991

One month before Senator Jesse Helms (R-NC), one of the most anti-gay senators in modern U.S. history and a chief obstacle to AIDS funding, was expected to obstruct new federal HIV appropriations, Staley led an ACT UP action that has since become iconic. On September 5, 1991, activists led by Staley climbed a scaffolding truck outside Helms's Arlington, Virginia home and covered the entire two-story house with a 35-foot inflatable condom reading "A CONDOM TO STOP UNSAFE POLITICS — HELMS IS DEADLIER THAN A VIRUS."10

The image was on every major U.S. newspaper front page the next morning. It remains one of the most reproduced images in modern American protest history.

Never Silent — Peter Staley today

Peter Staley did not die. Combination antiretroviral therapy came online in 1996, and he was among the earliest patients to benefit. His HIV has been undetectable ever since. He was a central subject of David France's 2012 documentary How to Survive a Plague, which was nominated for the 2013 Academy Award for Best Documentary Feature. His memoir Never Silent: ACT UP and My Life in Activism was published by Chicago Review Press in October 2021 to critical acclaim.4

He continues to work publicly on HIV, PrEP access (see PrEP page), pharmaceutical pricing, and LGBTQ political issues. In 2018-2020 he led the Prep4All coalition that successfully pushed the federal government to sue Gilead Sciences over PrEP patents — a case that alleged Gilead had improperly monetized patents developed with federal research funding, echoing exactly the argument he made about AZT in 1989.11

Timeline — 1961 to today

Questions people ask